A CDK12 / PARP dual-target inhibitor, its preparation method and application
By developing a CDK12/PARP dual-target inhibitor, combined with a specific chemical structure and synthesis method, the limitations of existing chemotherapy drugs and the problems of drug resistance have been solved, achieving highly effective treatment for a variety of cancers and reducing toxic side effects.
Patent Information
- Application Number
- CN202511298956.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-11
- Publication Date
- 2026-05-26
- Estimated Expiration
- 2045-09-11
AI Technical Summary
Existing chemotherapy drugs have limited efficacy in treating cancer and are prone to drug resistance. Existing PARP inhibitors have a narrow anti-tumor spectrum, which cannot cover all types of tumors, and the combination of drugs can produce significant toxic side effects, resulting in poor patient compliance.
A CDK12/PARP dual-target inhibitor was developed, combining the phthalazine-(2H)-one structure of the PARP inhibitor olaparib with the pharmacophore moiety of the CDK12 inhibitor to prepare compounds with CDK12 and PARP inhibitory activities. Compounds I-1 to I-25 were synthesized by specific chemical synthesis methods.
This inhibitor can significantly inhibit CDK12 and PARP, reduce drug dosage, reduce drug resistance, reduce the toxic side effects of combined drug use, and has a significant anti-proliferative effect on various cancers such as breast cancer and ovarian cancer.
Smart Images

Figure CN121248582B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a CDK12 / PARP dual-target inhibitor, its preparation method, and its application. Background Technology
[0002] Currently, cancer remains one of the leading diseases threatening human life and health, and its mortality rate is showing a significant upward trend. This seriously threatens human health, placing a heavy burden not only on global healthcare systems and economic development but also on families and societies. Under such a severe situation regarding cancer prevention and control, the demand for anti-cancer products is rapidly increasing. The treatment of malignant tumors mainly utilizes traditional chemotherapy drugs or radiotherapy; however, chemotherapy is highly toxic and lacks specificity. Therefore, finding highly effective and low-toxicity anti-tumor drugs is a highly challenging and significant topic in current medicinal chemistry research.
[0003] Studies have found that CDK12 is closely related to various cancer pathways, and some CDK12-related mutations, amplifications, deletions, and overexpressions are closely associated with the development of certain cancers. Some studies have also shown that certain CDK12 gene mutations and overexpressions are closely related to the development of various cancers. This is widespread in the occurrence and proliferation of cancers such as colon cancer, breast cancer, gastric cancer, and cervical cancer, and patients with these tumors generally have poor prognoses. Therefore, inhibiting CDK12 activity can effectively induce DNA damage caused by homologous recombination repair deficiency (HRD), thereby achieving the goal of killing cells. When CDK12 / 13 inhibitors are used in combination with other drugs, they can exhibit a synergistic effect, which can significantly enhance the killing power against cancer cells, help overcome the problem of drug resistance in cancer cells, and reduce the emergence of drug-resistant cell lines. (Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12 / 13 covalent inhibitor with...)
[0004] Efficacy in Ewing sarcoma (Eur.J.Med.Chem.(2021), 221, 113481); Therapeutic Targeting of CDK12 / CDK13 in Triple Negative Breast Cancer (CancerCell (2019), 36(5), 545-558.e7)). Furthermore, CDK12 exhibits synthetic lethal interactions with MYC, WS / FLI fusions, and PARP inhibitors (PARPi), suggesting that these interactions can lead to cell death, thus providing a novel potential strategy for cancer treatment.
[0005] Poly(ADP-ribose) polymerases (PARPs) are a superfamily of proteins in eukaryotic cells that catalyze the ADP-ribosylation of proteins, comprising at least 17 protein subtypes. PARP catalyzes the cleavage of the substrate nicotinamide adenine dinucleotide NAD+ into nicotinamide and ADP-ribose, and causes poly-ADP-ribosylation of its target proteins. PARP is located in the cell nucleus and is a key enzyme in cellular DNA damage repair. Numerous studies have shown that abnormal increases in PARP1 are closely associated with the occurrence of various cancers, such as ovarian cancer and breast cancer. Due to the high conservation of the amino acid sequence of the catalytic center in the PARP1 structure, it has attracted widespread attention from medicinal chemists. This conservation makes PARP1 an extremely important target in the development of anticancer drugs (Advances in Development of Selective Antitumor Inhibitors That Target PARP-1 (J.Med.Chem.(2023), 66(24), 16464-16483)).
[0006] Currently, four PARP inhibitors are in clinical use: olaparib, rucaparib, niraparib, and talazoparib. These inhibitors are approved for the treatment of breast cancer, ovarian cancer, pancreatic cancer, and bladder cancer. However, with the further use of these inhibitors, some limitations have become apparent. On the one hand, the existing inhibitors have a relatively narrow anti-tumor spectrum, failing to cover all types of tumors (Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions). On the other hand, with long-term clinical use of these inhibitors, tumor cells may develop resistance, leading to decreased treatment efficacy. Several strategies have been developed to overcome PARP inhibitor resistance, including dual-target inhibitors and combination therapies. However, combination therapies can produce significant toxic side effects and poor patient adherence, reducing patients' quality of life. Therefore, developing dual-target inhibitors could reduce the proliferation of drug-resistant tumor cells and provide more controllable pharmacokinetic data. Several dual-target inhibitors targeting PARP have been reported, and their efficacy is superior to that of single-target PARP inhibitors (Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer (Eur.J.Med.Chem.(2023), 259, 115648)).
[0007] Therefore, it is urgent to develop a CDK12 / PARP dual-target inhibitor. Summary of the Invention
[0008] The purpose of this invention is to provide a CDK12 / PARP dual-target inhibitor, its preparation method, and its application in order to solve the above-mentioned problems. The inhibitor has the phthalazine-(2H)-one structure of the PARP inhibitor olaparib and the pharmacophore of the CDK12 inhibitor. Experiments show that it has good CDK12 and PARP inhibitory activity and can be used to prepare drugs for treating cancer.
[0009] The objective of this invention is achieved through the following technical solution:
[0010] This invention provides a CDK12 / PARP dual-target inhibitor having the chemical structural formula shown in general formula (I):
[0011] (I),
[0012] Where A is selected from any of the following structural formulas:
[0013] , , , , , , , , , , , , , , , , , , , or .
[0014] Furthermore, Ar is selected from any of the following structural formulas:
[0015] , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .
[0016] Furthermore, the hydrogen atom bonded to the carbon atom in general formula (I) can be replaced with the hydrogen isotope deuterium.
[0017] Furthermore, A is selected from any of the following structural formulas:
[0018] , or .
[0019] Furthermore, Ar is selected from any of the following structural formulas:
[0020] , , , , , , , , , , , , , , , , , , , or .
[0021] Furthermore, CDK12 / PARP dual-target inhibitors include any one of the following compounds:
[0022] I-1: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-nitropyrimidin-2-yl)amino)cyclohexyl)acetamide;
[0023] I-2: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-(trifluoromethyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide;
[0024] I-3: N-((1r,4r)-4-((5-cyanopyrimidine-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide;
[0025] I-4: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)acetamide;
[0026] I-5: N-((1r,4r)-4-((5-chloropyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide;
[0027] I-6: N-((1r,4r)-4-((5-bromopyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide;
[0028] I-7: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-iodopyrimidin-2-yl)amino)cyclohexyl)acetamide;
[0029] I-8: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-nitropyridin-2-yl)amino)cyclohexyl)acetamide;
[0030] I-9: N-((1r,4r)-4-((5-cyanopyridin-2-yl))amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide;
[0031] I-10: N-((1r,4r)-4-((7-bromoquinazolin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide;
[0032] I-11: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide;
[0033] I-12: N-((1r,4r)-4-((4-(ethylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide;
[0034] I-13: N-((1r,4r)-4-((4-(ethylamino)-5-fluoropyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide;
[0035] I-14: N-(4-(N-((1r,4r)-4-((5-chloro-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide;
[0036] I-15: N-(4-(N-((1r,4r)-4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide;
[0037] I-16: N-(4-(N-((1r,4r)-4-((4-((3-bromophenyl)amino)-5-chloropyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide;
[0038] I-17: N-(4-(N-((1r,4r)-4-((5-chloro-4-(4-fluorophenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide;
[0039] I-18: N-(4-(N-((1r,4r)-4-((5-chloro-4-(4-methoxyphenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide;
[0040] I-19: N-(4-(N-((1r,4r)-4-((5-chloro-4-((3-fluorophenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide;
[0041] I-20: N-(4-(N-((1r,4r)-4-((4-((3-acetamidophenyl)amino)-5-chloropyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazine-1-yl)methyl)benzamide;
[0042] I-21: 2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)-N-(4-(N-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)acetamyl)phenyl)benzamide;
[0043] I-22: N-(3-(N-((1r,4r)-4-((5-chloropyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide;
[0044] I-23: N-(3-(N-((1r,4r)-4-((5-cyanopyrimidine-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide;
[0045] I-24: N-(3-(N-((1r,4r)-4-((5-chloro-4-(4-methoxyphenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide;
[0046] I-25: N-(3-(N-((1r,4r)-4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide.
[0047] Furthermore, a method for preparing the above-mentioned CDK12 / PARP dual-target inhibitor includes the following steps:
[0048] Step 1:
[0049]
[0050] Step Two:
[0051]
[0052] Step 3:
[0053]
[0054] Step Four:
[0055]
[0056] Where A and Ar are defined as in the claims;
[0057] Furthermore, in step four, the solvent is dioxane hydrochloride solution. The reaction is stirred at room temperature until Boc is completely removed. Anhydrous diethyl ether is added to the reaction solution, the mixture is sonicated, the liquid is poured out, washed with anhydrous diethyl ether, and the solvent is removed under vacuum.
[0058] Ar-X, DIPEA, and dry NMP were then added, and the mixture was stirred at 100-150°C under nitrogen protection. The reaction was monitored by TLC until it ended. The mixture was then extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, mixed with silica gel, and subjected to column chromatography to obtain the CDK12 / PARP dual-target inhibitor.
[0059] The present invention also provides the use of the above-mentioned CDK12 / PARP dual-target inhibitor in the preparation of drugs for the in vitro prevention, treatment or adjuvant treatment of cancer or for cancer prevention; and in the preparation of drugs for the in vitro inhibition of cancer cell proliferation.
[0060] Furthermore, the cancer mentioned is one or more of breast cancer, ovarian cancer, lung cancer, hematologic malignancies, prostate cancer, pancreatic cancer, lymphoma, and stomach cancer.
[0061] The present invention also provides the use of the above-mentioned CDK12 / PARP dual-target inhibitor, its compound, its salt, its stereoisomer or its solvate in the preparation of CDK12 inhibitors and / or PARP inhibitors.
[0062] The present invention has the following beneficial effects:
[0063] (1) A single active ingredient can exert a dual inhibitory effect on CDK12 and PARP, reducing the dosage, improving the therapeutic effect, reducing drug resistance, and reducing the toxic side effects of combined drug use;
[0064] (2) It has a significant dual inhibitory effect on CDK12 and PARP, and a significant anti-proliferative effect on tumor cells;
[0065] (3) It has wide applicability, and drugs with it as an active ingredient can be used to treat a variety of cancers or tumors related to CDK12 and / or PARP. Attached Figure Description
[0066] Figure 1 Chemical reaction equation for the preparation of CDK12 / PARP dual-target inhibitors. Detailed Implementation
[0067] Example 1
[0068] N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-nitropyrimidine-2-yl)amino)cyclohexyl)acetamide (compound I-1), the structural formula of which is shown in the following formula:
[0069]
[0070] (1) Step 1: tert-butyl((1R,4R)-4-((4-(4-(2,2-trifluoroacetyl)piperazin-1-yl)phenyl)amino)cyclohexyl)carbamate (intermediate 1)
[0071]
[0072] 2,2,2-trifluoro-1-(4-(4-iodophenyl)piperazin-1-yl)acetate-1-one (7.6798 g, 20 mmol), trans-(4-aminocyclohexyl)carbamate tert-butyl ester (6.4290 g, 30 mmol), cuprous iodide (0.3809 g, 2 mmol), D-proline (0.2303 g, 2 mmol), and potassium phosphate (8.4908 g, 40 mmol) were added to 50 mL of dry DMSO. The mixture was purged with nitrogen three times and stirred at 100 °C for 16 hours under nitrogen protection. The reaction was monitored by TLC until the reaction was complete. The mixture was then extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, mixed with silica gel, and subjected to column chromatography to obtain 4.1382 g of white solid, with a yield of 44%.
[0073] The 1H NMR spectrum data of intermediate 1 are as follows: 1 H NMR (500 MHz, CDCl3) δ 6.84 (d, J = 8.8 Hz, 2H), 6.58 (d, J = 8.7 Hz, 2H), 4.42 (s, 1H), 3.90 – 3.81 (m, 2H), 3.79 – 3.71(m, 2H), 3.48 (s, 1H), 3.30 (s, 1H), 3.23 – 3.12 (m, 1H), 3.12 – 3.02 (m,4H), 2.12 (dd, J = 33.5, 8.9 Hz, 4H), 1.47 (s, 9H), 1.24 (dd, J = 14.6, 9.2 Hz, 4H);
[0074] (2) Step 2: tert-butyl((1r,4r)-4-(N-(4-(4-(2,2,2-trifluoroacetyl)piperazin-1-yl)phenyl)acetamido)cyclohexyl)carbamate (intermediate 2)
[0075]
[0076] Accurately weigh intermediate 1 (9.4050 g, 20 mmol) into a 100 mL round-bottom flask, add 60 mL of dry tetrahydrofuran, and add 20.0 mL (100 mmol) of DIPEA to the system using a 50 mL disposable syringe. Then, accurately add 6.0 mL (60 mmol) of acetyl chloride dropwise to the system using a 10 mL disposable syringe. React at 0 °C for 2 hours. After the reaction is complete, pour 10 mL of cold water into the reaction solution, add 3 x 60 mL of ethyl acetate for extraction three times, combine the organic phases, wash successively with water and saturated brine, dry the organic phase with anhydrous sodium sulfate, remove the solvent under vacuum, and obtain 9.8354 g of white solid by column chromatography, with a yield of 96%.
[0077] The 1H NMR spectrum data of intermediate 2 are as follows: 1 H NMR (500 MHz, CDCl3) δ 6.96 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 4.57 (ddd, J = 11.9, 7.8, 3.6 Hz, 1H), 4.34 (s,1H), 3.91 – 3.84 (m, 2H), 3.83 – 3.75 (m, 2H), 3.33 – 3.23 (m, 4H), 3.16 (s,1H), 1.96 (d, J = 11.4 Hz, 2H), 1.81 (d, J = 11.6 Hz, 2H), 1.73 (s, 3H), 1.40 (s, 9H), 1.30 – 1.12 (m, 4H);
[0078] (3) Step 3: tert-butyl ((1r,4r)-4-(N-(4-(4-(2-fluoro-5-(4-oxo-3,4-dihydrobenzothiazol-1-ylmethyl)phenyl)acetamyl)phenyl)propionamide))carboxylic acid ester (intermediate 3)
[0079]
[0080] Take intermediate 2 (5.1226 g, 10 mmol) and potassium carbonate (7.1869 g, 52 mmol) into a 50 mL round-bottom flask, and add 20 mL of [unspecified solution]. A methanol solution was heated and stirred in an oil bath at 65°C for 2 hours. The reaction solution was then cooled and extracted three times with 3 x 30 mL of dichloromethane. The organic phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the solvent was removed under vacuum to obtain a white solid. Then, 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid (3.5792 g, 12 mmol), HATU (4.1825 g, 11 mmol), and triethylamine (2.11 mL, 15 mmol) were added, followed by 15 mL of dry DMF. The reaction was carried out at room temperature for 16 hours. After the reaction was complete, 10 mL of cold water was added to the reaction solution, and the mixture was stirred for 1 hour. The mixture was filtered, and the filter cake was collected. The filter cake was washed three times with 3 x 10 mL of ethyl acetate, and then three times with 3 x 10 mL of water to obtain 5.9189 g of white solid, with a yield of 85%.
[0081] The 1H NMR spectrum data of intermediate 3 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.21 (s, 1H), 8.49– 8.44 (m, 1H), 7.81 – 7.70 (m, 3H), 7.37 (dd, J = 6.1, 2.1 Hz, 1H), 7.35 –7.29 (m, 1H), 7.06 (t, J = 8.8 Hz, 1H), 6.94 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.8Hz, 2H), 4.56 (ddd, J = 11.8, 8.2, 3.6 Hz, 1H), 4.33 (s, 1H), 3.96 (s, 2H), 3.48 (s, 2H), 3.31 (t, J = 4.9 Hz, 2H), 3.16 (s, 3H), 1.96 (d, J = 11.2 Hz, 2H), 1.81 (d, J = 11.6 Hz, 2H), 1.73 (s, 3H), 1.40 (s, 9H), 1.28 – 1.12 (m, 4H);
[0082] (4) Step 4: Preparation of compound I-1
[0083]
[0084] Add 2 mL of dioxane hydrochloride solution to intermediate 3 (0.0696 g, 0.1 mmol), stir at room temperature for 2 h, and monitor the reaction progress by TLC until Boc is completely removed. Add anhydrous diethyl ether to the reaction solution, sonicate, pour off the liquid, wash twice with anhydrous diethyl ether, and remove the solvent under vacuum. Then add 2-chloro-5-nitropyrimidine (0.0191 g, 0.12 mmol), DIPEA (0.11 mL, 0.6 mmol), and 2 mL of dry NMP. Purify with nitrogen three times, stir at 120 °C for 16 h under nitrogen protection, and monitor the reaction end by TLC. Extract with ethyl acetate, wash with saturated brine, dry with anhydrous sodium sulfate, concentrate under reduced pressure, mix with silica gel, and column chromatography to obtain 0.0626 g of white solid, with a yield of 87%.
[0085] The 1H NMR spectrum data of compound I-1 are as follows: 1 H NMR (500 MHz, CDCl3) δ 11.51 (s, 1H), 8.98 (s, 2H), 8.47 (d, J = 7.6 Hz, 1H), 7.81 – 7.67 (m, 3H), 7.41 – 7.29 (m,2H), 7.05 (t, J = 8.7 Hz, 1H), 6.96 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 6.69 (d, J = 8.1 Hz, 1H), 4.65 (t, J = 12.0 Hz, 1H), 4.30 (s, 2H), 3.95 (s, 2H), 3.76 – 3.63 (m, 1H), 3.48 (s, 2H), 3.31 (s, 2H), 3.16 (s, 2H), 2.07 (d, J =11.2 Hz, 2H), 1.89 (d, J = 11.6 Hz, 2H), 1.75 (s, 3H), 1.49 (q, J = 11.5 Hz, 2H), 1.26 (dd, J = 23.8, 11.4 Hz, 2H);
[0086] The carbon NMR data of compound I-1 are as follows: 13C NMR (126 MHz, CDCl3) δ 170.95, 165.08,162.43, 160.93, 157.15 (d, J = 247.8 Hz), 155.44, 155.19, 150.57, 145.70,134.45 (d, J = 3.5 Hz), 134.27, 133.78, 131.73 (d, J = 6.5 Hz), 131.33, 130.87,129.65, 129.36 (d, J = 3.4 Hz), 128.35, 127.26, 125.14, 123.96 (d, J = 18.1 Hz), 116.63, 116.28 (d, J = 21.9 Hz), 52.50, 50.25, 49.27, 48.97, 46.90, 42.01,37.79, 31.61, 29.68, 23.48;
[0087] The NMR fluorine spectrum data of compound I-1 are as follows: 19 F NMR (471 MHz, CDCl3) δ -117.50.
[0088] Example 2
[0089] N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-(trifluoromethyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide (compound I-2)
[0090]
[0091] Using intermediate 3 and 2-chloro-5-trifluoromethylpyrimidine as raw materials, the same method as that used in Example 1 was followed to prepare I-1.
[0092] White solid, yield 60%;
[0093] The 1H NMR spectrum data of compound I-2 are as follows: 1H NMR (500 MHz, CDCl3) δ 11.80 (s, 1H), 8.51 – 8.43 (m, 1H), 8.38 (s, 2H), 7.81 – 7.67 (m, 3H), 7.36 (dd, J = 6.1, 2.0Hz, 1H), 7.34 – 7.29 (m, 1H), 7.03 (t, J = 8.8 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.9 Hz, 2H), 6.08 (d, J = 8.1 Hz, 1H), 4.72 – 4.54 (m, 1H), 4.29 (s,2H), 3.94 (s, 2H), 3.67 – 3.53 (m, 1H), 3.47 (s, 2H), 3.29 (s, 2H), 3.14 (s,2H), 2.06 (d, J = 11.1 Hz, 2H), 1.85 (d, J = 11.3 Hz, 2H), 1.73 (s, 3H), 1.42(dd, J = 18.4, 5.9 Hz, 2H), 1.34 – 1.17 (m, 2H);
[0094] The carbon NMR data of compound I-2 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.9, 165.1,162.6, 161.0, 157.1 (d, J = 247.7 Hz), 155.8, 150.5, 145.7, 134.5 (d, J = 3.3Hz), 133.7, 131.7 (d, J = 6.2 Hz), 131.4, 130.9, 129.6, 129.3 (d, J = 3.3 Hz),128.3, 127.2, 125.1, 123.9 (d, J = 18.0 Hz), 123.0, 116.6, 116.2 (d, J = 21.9Hz), 113.7 (d, J= 34.0 Hz), 52.6, 49.5, 49.3, 49.0, 46.9, 42.0, 37.8, 31.8,29.7, 23.4;
[0095] The NMR fluorine spectrum data of compound I-2 are as follows: 19 F NMR (471 MHz, CDCl3) δ -61.09, -117.54.
[0096] Example 3
[0097] N-((1r,4r)-4-((5-cyanopyrimidine-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide (compound I-3)
[0098]
[0099] Using intermediate 3 and 2-chloro-5-cyanopyrimidine as raw materials, the same method as that used in Example 1 was followed to prepare I-1.
[0100] White solid, yield 75%;
[0101] The 1H NMR spectrum data of compound I-3 are as follows: 1 H NMR (500 MHz, CDCl3) δ 11.67 (s, 1H),8.46 (d, J = 7.0 Hz, 1H), 8.40 (s, 2H), 7.78 – 7.69 (m, 3H), 7.38 – 7.29 (m,2H), 7.03 (t, J = 8.8 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 6.37 (d, J = 8.1 Hz, 1H), 4.63 (ddd, J = 12.1, 8.7, 3.5 Hz, 1H), 4.29 (s, 2H), 3.93 (s, 2H), 3.66 – 3.55 (m, 1H), 3.46 (s, 2H), 3.29 (s, 2H), 3.14 (s, 2H), 2.04 (d, J = 11.2 Hz, 2H), 1.86 (d,J = 11.2 Hz, 2H), 1.73 (s, 3H), 1.50 – 1.37 (m, 2H), 1.29 – 1.14 (m, 2H);
[0102] The carbon NMR data of compound I-3 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.9, 165.0,161.4, 161.1, 161.0, 160.8, 157.0 (d, J = 247.7 Hz), 150.5, 145.6, 134.4 (d, J =3.0 Hz), 133.7, 131.6 (d, J = 9.1 Hz), 131.2, 130.8, 129.6, 129.3 (d, J = 3.3Hz), 128.3, 127.1, 125.1, 123.8 (d, J = 18.0 Hz), 116.6, 116.2 (d, J = 21.9 Hz),96.3, 52.5, 49.6, 49.2, 48.9, 46.8, 41.9, 37.7, 31.5, 29.6, 23.4;
[0103] The NMR fluorine spectrum data of compound I-3 are as follows: 19 F NMR (471 MHz, CDCl3) δ -117.50.
[0104] Example 4
[0105] N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)acetamide (compound I-4)
[0106]
[0107] Using intermediate 3 and 2-chloroquinazoline as raw materials, the same method as that used in Example 1 was followed to prepare I-1.
[0108] White solid, yield 45%;
[0109] The 1H NMR spectrum data of compound I-4 are as follows: 1H NMR (500 MHz, CDCl3) δ 10.62 (s, 1H), 8.91 (s, 1H), 8.50 – 8.40 (m, 1H), 7.82 – 7.71 (m, 3H), 7.63 (t, J = 8.6 Hz, 2H), 7.50 (d, J = 8.4 Hz, 1H), 7.40 – 7.30 (m, 2H), 7.19 (t, J = 7.5 Hz, 1H), 7.07 (t, J = 8.7 Hz, 1H), 6.99 (d, J = 8.7 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 5.27(d, J = 21.4 Hz, 1H), 4.67 (ddd, J = 11.9, 8.4, 3.7 Hz, 1H), 4.30 (s, 2H), 3.97(s, 2H), 3.78 – 3.62 (m, 1H), 3.49 (s, 2H), 3.33 (t, J = 4.8 Hz, 1H), 3.17 (s,2H), 2.19 (d, J = 11.2 Hz, 2H), 1.88 (d, J = 11.3 Hz, 2H), 1.76 (s, 3H), 1.49 –1.23 (m, 4H);
[0110] The carbon NMR data of compound I-4 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.8, 165.1,162.1, 160.5, 157.2 (d, J = 247.6 Hz), 152.3, 150.6, 145.7, 134.4 (d, J = 14.4Hz), 133.8, 131.8 (d, J = 2.2 Hz), 131.0, 129.7, 129.5 (d, J = 3.7 Hz), 128.5,127.7, 127.4, 125.2, 122.6, 120.2, 116.7, 116.4 (d, J= 21.8 Hz), 52.9, 49.4,49.1, 47.0, 42.1, 37.9, 32.3, 30.0, 23.6;
[0111] The NMR fluorine spectrum data of compound I-4 are as follows: 19 F NMR (471 MHz, CDCl3) δ -117.42.
[0112] Example 5
[0113] N-((1r,4r)-4-((5-chloropyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide (compound I-5)
[0114]
[0115] Using intermediate 3 and 2,5-dichloropyrimidine as raw materials, the same method as that used in Example 1 was followed to prepare I-1.
[0116] White solid, yield 60%;
[0117] The 1H NMR spectrum data of compound I-5 are as follows: 1 H NMR (500 MHz, CDCl3) δ 11.29 (s, 1H),8.51 – 8.43 (m, 1H), 8.13 (s, 2H), 7.80 – 7.69 (m, 3H), 7.40 – 7.35 (m, 1H),7.35 – 7.30 (m, 1H), 7.05 (t, J = 8.8 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 5.36 – 5.23 (m, 1H), 4.63 (tt, J = 11.8, 3.4 Hz, 1H), 4.30 (s,2H), 3.95 (s, 2H), 3.49 (dd, J = 11.4, 7.7 Hz, 3H), 3.30 (t, J = 4.6 Hz, 2H), 3.15 (s, 2H), 2.06 (d, J = 11.3 Hz, 2H), 1.85 (d,J = 11.8 Hz, 2H), 1.74 (s, 3H), 1.44 – 1.32 (m, 2H), 1.30 – 1.19 (m, 2H);
[0118] The carbon NMR data for compound I-5 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.8, 165.1,160.8, 160.0, 156.2 (d, J = 12.7 Hz), 150.5, 145.6, 134.5 (d, J = 3.2 Hz), 133.8,131.7 (d, J = 6.7 Hz), 131.6, 130.9, 129.7, 129.4 (d, J = 3.5 Hz), 128.4, 127.3,125.2, 124.0 (d, J = 18.1 Hz), 118.6, 116.7, 116.3 (d, J = 21.9 Hz), 52.7, 49.7,49.4, 49.1, 46.9, 42.0, 37.8, 32.0, 29.8, 23.5;
[0119] The NMR fluorine spectrum data of compound I-5 are as follows: 19 F NMR (471 MHz, CDCl3) δ -117.48.
[0120] Example 6
[0121] N-((1r,4r)-4-((5-bromopyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide (compound I-6)
[0122]
[0123] Using intermediates 3 and 5-bromo-2-chloropyrimidine as raw materials, the same method as that used in Example 1 was employed to prepare I-1.
[0124] White solid, yield 55%;
[0125] The 1H NMR spectrum data of compound I-6 are as follows: 1H NMR (500 MHz, CDCl3) δ 11.41 (s, 1H), 8.62 – 8.35 (m, 1H), 8.19 (s, 2H), 7.75 (tt, J = 16.1, 7.2 Hz, 3H), 7.39 – 7.34(m, 1H), 7.35 – 7.29 (m, 1H), 7.04 (t, J = 8.8 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 5.37 (d, J = 8.1 Hz, 1H), 4.62 (t, J = 3.6 Hz, 1H), 4.30(s, 2H), 3.95 (s, 2H), 3.47 (d, J = 3.6 Hz, 3H), 3.30 (t, J = 4.7 Hz, 2H), 3.15(s, 2H), 2.06 (d, J = 11.7 Hz, 2H), 1.84 (d, J = 11.4 Hz, 2H), 1.73 (s, 3H), 1.37(dd, J = 24.0, 11.3 Hz, 2H), 1.23 (td, J = 12.3, 10.0 Hz, 2H);
[0126] The carbon NMR data of compound I-6 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.9, 165.1,160.9, 160.0, 158.3, 157.2 (d, J = 247.9 Hz), 150.5, 145.7, 134.4 (d, J = 3.5Hz), 133.8, 131.7 (d, J = 5.2 Hz), 130.9, 129.7, 129.4 (d, J = 3.4 Hz), 128.4,127.3, 125.2, 124.0 (d, J = 18.0 Hz), 116.7, 116.3 (d, J= 22.0 Hz), 105.9, 52.7,49.6, 49.3, 49.1, 46.9, 42.0, 37.8, 32.0, 29.8, 23.5;
[0127] The NMR fluorine spectrum data of compound I-6 are as follows: 19 F NMR (471 MHz, CDCl3) δ -117.49.
[0128] Example 7
[0129] N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-iodopyrimidin-2-yl)amino)cyclohexyl)acetamide (compound I-7)
[0130]
[0131] Using intermediate 3 and 2-chloro-5-iodopyrimidine as raw materials, the same method as that used in Example 1 was employed to prepare I-1.
[0132] White solid, yield 73%;
[0133] The 1H NMR spectrum data of compound I-7 are as follows: 1 H NMR (500 MHz, CDCl3) δ 11.37 (s, 1H), 8.52 – 8.43 (m, 1H), 8.29 (s, 2H), 7.80 – 7.69 (m, 3H), 7.37 (dd, J = 6.0, 1.9Hz, 1H), 7.34 – 7.30 (m, 1H), 7.04 (t, J = 8.8 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 5.35 (d, J = 8.1 Hz, 1H), 4.62 (tt, J = 11.9, 3.5 Hz,1H), 4.30 (s, 2H), 3.95 (s, 2H), 3.55 – 3.39 (m, 3H), 3.30 (t, J = 4.7 Hz, 2H),3.15 (s, 2H), 2.05 (d, J= 11.2 Hz, 2H), 1.84 (d, J = 11.3 Hz, 2H), 1.73 (s, 3H), 1.38 (dt, J = 24.4, 6.5 Hz, 2H), 1.30 – 1.11 (m, 2H);
[0134] The carbon NMR data for compound I-7 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.9, 165.1,162.9, 160.8, 159.9, 157.2 (d, J = 247.8 Hz), 150.5, 145.7, 134.4 (d, J = 3.2Hz), 133.8, 131.7 (d, J = 6.3 Hz), 131.5, 130.9, 129.7, 129.4 (d, J = 3.6 Hz),128.4, 127.3, 125.2, 124.0 (d, J = 18.0 Hz), 116.7, 116.3 (d, J = 21.8 Hz), 75.4,52.7, 49.5, 49.3, 49.1, 46.9, 42.0, 37.8, 31.9, 29.8, 23.5;
[0135] The NMR fluorine spectrum data of compound I-7 are as follows: 19 F NMR (471 MHz, CDCl3) δ -117.48.
[0136] Example 8
[0137] N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-nitropyridin-2-yl)amino)cyclohexyl)acetamide (compound I-8)
[0138]
[0139] Using intermediate 3 and 2-fluoro-5-nitropyridine as raw materials, the same method as that used in Example 1 was employed to prepare I-1.
[0140] Yellow solid, yield 89%;
[0141] The 1H NMR spectrum data of compound I-8 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.94 (s, 1H),8.92 (d, J = 2.6 Hz, 1H), 8.57 – 8.31 (m, 1H), 8.07 (dd, J = 9.1, 1.9 Hz, 1H), 7.76 (ddd, J = 16.5, 11.0, 4.8 Hz, 3H), 7.47 – 7.29 (m, 2H), 7.06 (t, J = 8.7 Hz, 1H), 6.97 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 6.29 (d, J = 9.3 Hz, 1H), 5.74 (d, J = 5.3 Hz, 1H), 4.66 (ddd, J = 12.0, 8.5, 3.6 Hz, 1H), 4.30 (s, 2H), 3.96 (s, 2H), 3.77 – 3.55 (m, 1H), 3.49 (s, 2H), 3.32 (t, J = 4.5 Hz, 2H), 3.16(s, 2H), 2.09 (d, J = 11.2 Hz, 2H), 1.89 (d, J = 11.4 Hz, 2H), 1.76 (s, 3H), 1.44(dd, J = 24.0, 11.4 Hz, 2H), 1.28 (dd, J = 22.5, 12.0 Hz, 2H);
[0142] The carbon NMR data for compound I-8 are as follows: 13 C NMR (126 MHz, CDCl3) δ 171.0, 165.1,160.7, 160.6, 157.2 (d, J = 247.6 Hz), 150.7, 147.2, 145.7, 135.5, 134.5 (d, J =3.3 Hz), 133.8, 131.8 (d, J= 6.5 Hz), 131.3, 130.9, 129.7, 129.4 (d, J = 3.6Hz), 128.5, 127.3, 125.2, 124.0 (d, J = 18.2 Hz), 116.7, 116.3 (d, J = 21.8 Hz),52.7, 49.3, 49.0, 46.9, 42.0, 37.8, 32.0, 29.8, 23.6;
[0143] The NMR fluorine spectrum data of compound I-8 are as follows: 19 F NMR (471 MHz, CDCl3) δ -117.50.
[0144] Example 9
[0145] N-((1r,4r)-4-((5-cyanopyridin-2-yl))amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide (compound I-9)
[0146]
[0147] Using intermediates 3 and 6-fluoronicotinonitrile as raw materials, the same method as that used in Example 1 was employed to prepare I-1.
[0148] White solid, yield 55%;
[0149] The 1H NMR spectrum data of compound I-9 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.28 (s, 1H),8.52 – 8.42 (m, 1H), 8.28 (d, J = 2.0 Hz, 1H), 7.82 – 7.70 (m, 3H), 7.48 (dd, J =8.8, 2.2 Hz, 1H), 7.40 – 7.29 (m, 2H), 7.07 (t, J = 8.8 Hz, 1H), 6.97 (d, J = 8.8Hz, 2H), 6.90 (d, J = 8.9 Hz, 2H), 6.28 (d, J= 8.8 Hz, 1H), 4.94 (d, J = 6.6 Hz, 1H), 4.65 (tt, J = 11.8, 3.6 Hz, 1H), 4.30 (s, 2H), 3.96 (s, 2H), 3.49 (s, 3H), 3.32 (t, J = 4.9 Hz, 2H), 3.16 (s, 2H), 2.08 (d, J = 11.5 Hz, 2H), 1.88 (d, J =11.2 Hz, 2H), 1.75 (s, 3H), 1.39 (dd, J = 24.3, 10.6 Hz, 2H), 1.34 – 1.20 (m,2H);
[0150] The carbon NMR data for compound I-9 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.9, 165.1,160.6, 159.1, 157.2 (d, J = 247.6 Hz), 153.3, 150.6, 134.4 (d, J = 3.5 Hz), 133.8, 131.8 (d, J = 4.5 Hz), 131.4, 130.9, 129.7, 129.4 (d, J = 3.2 Hz), 128.5,127.3, 125.2, 124.0 (d, J = 18.2 Hz), 118.8, 116.7, 116.3 (d, J = 21.7 Hz), 96.5,52.7, 49.5, 49.4, 49.0, 46.9, 42.0, 37.8, 32.1, 29.8, 23.5;
[0151] The NMR fluorine spectrum data of compound I-9 are as follows: 19 F NMR (471 MHz, CDCl3) δ -117.43.
[0152] Example 10
[0153] N-((1r,4r)-4-((7-bromoquinazolin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide (compound I-10)
[0154]
[0155] Using intermediates 3 and 7-bromo-2-chloroquinazoline as raw materials, the same method as that used in Example 1 was employed to prepare I-1.
[0156] White solid, yield 75%;
[0157] The 1H NMR spectrum data of compound I-10 are as follows: 1 H NMR (500 MHz, CDCl3) δ 11.36 (s, 1H), 8.83 (s, 1H), 8.53 – 8.42 (m, 1H), 7.82 – 7.70 (m, 4H), 7.65 (dd, J = 9.0, 2.1Hz, 1H), 7.41 – 7.36 (m, 2H), 7.35 – 7.30 (m, 1H), 7.06 (t, J = 8.8 Hz, 1H), 6.98 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 5.49 (s, 1H), 4.66 (ddd, J =12.0, 8.5, 3.6 Hz, 1H), 4.31 (s, 2H), 3.96 (s, 2H), 3.75 – 3.65 (m, 1H), 3.49(s, 2H), 3.32 (d, J = 4.5 Hz, 2H), 3.16 (s, 2H), 2.16 (d, J = 10.8 Hz, 2H), 1.88(d, J = 10.0 Hz, 2H), 1.75 (s, 3H), 1.43 (dd, J = 23.7, 11.4 Hz, 2H), 1.29 (dt, J =22.1, 10.9 Hz, 2H);
[0158] The carbon NMR data for compound I-10 are as follows:13 C NMR (126 MHz, CDCl3) δ 170.7, 165.0,160.9, 160.7, 157.1 (d, J = 247.6 Hz), 151.0, 150.4, 145.5, 137.4, 134.4 (d, J =3.4 Hz), 133.7, 131.6 (d, J = 7.9 Hz), 130.9, 129.6, 129.5, 129.3 (d, J = 3.1Hz), 128.4, 127.2, 125.1, 123.9 (d, J = 18.2 Hz), 121.0, 116.5, 116.2 (d, J =21.8 Hz), 114.8, 52.8, 49.2, 49.0, 46.9, 42.0, 37.7, 32.1, 29.8, 23.4;
[0159] The NMR fluorine spectrum data of compound I-10 are as follows: 19 F NMR (471 MHz, CDCl3) δ -117.48.
[0160] Example 11
[0161] N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide (compound I-11)
[0162]
[0163] Using intermediate 3 and 2-chloro-N-methyl-5-(trifluoromethyl)pyrimidin-4-amine as raw materials, the method for preparing I-1 in Example 1 was followed.
[0164] White solid, yield 50%;
[0165] The 1H NMR spectrum data of compound I-11 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.85 (s, 1H),8.47 (d, J= 7.3 Hz, 1H), 8.02 (s, 1H), 7.83 – 7.67 (m, 3H), 7.35 (dd, J = 10.6, 4.8 Hz, 2H), 7.06 (t, J = 8.7 Hz, 1H), 6.98 (d, J = 8.5 Hz, 2H), 6.91 (d, J = 8.5Hz, 2H), 5.46 (s, 1H), 4.75 (s, 1H), 4.63 (t, J = 11.9 Hz, 1H), 4.30 (s, 2H), 3.96 (s, 2H), 3.77 (s, 1H), 3.48 (s, 2H), 3.32 (s, 2H), 3.17 (s, 2H), 2.90(d, J = 3.5 Hz, 3H), 2.12 (s, 2H), 1.88 (d, J = 11.3 Hz, 2H), 1.74 (s, 3H), 1.37(dd, J = 23.6, 11.6 Hz, 2H), 1.29 – 1.15 (m, 2H);
[0166] The carbon NMR data for compound I-11 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.8, 165.1,163.7, 160.8, 158.2, 156.3 (d, J = 31.7 Hz), 154.9, 150.5, 145.6, 134.5 (d, J =3.0 Hz), 133.8, 131.7 (d, J = 3.2 Hz), 131.0, 129.7, 129.4 (d, J = 3.0 Hz),128.5, 127.3, 125.2, 124.0 (d, J = 17.4 Hz), 116.6, 116.3 (d, J = 21.7 Hz), 52.9,49.3, 49.0, 46.9, 42.0, 37.8, 31.9, 29.9, 28.3, 23.5;
[0167] The NMR fluorine spectrum data of compound I-11 are as follows:19 F NMR (471 MHz, CDCl3) δ -60.82, -117.55.
[0168] Example 12
[0169] N-((1r,4r)-4-((4-(ethylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide (compound I-12)
[0170]
[0171] Using intermediate 3 and 2-chloro-N-ethyl-5-(trifluoromethyl)pyrimidin-4-amine as raw materials, the procedure was the same as that used in Example 1 to prepare I-1;
[0172] White solid, yield 45%;
[0173] The 1H NMR spectrum data of compound I-12 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.84 (s, 1H),8.54 – 8.43 (m, 1H), 8.01 (s, 1H), 7.84 – 7.67 (m, 3H), 7.39 – 7.29 (m, 2H),7.06 (t, J = 8.7 Hz, 1H), 6.99 (d, J = 8.7 Hz, 2H), 6.92 (d, J = 8.7 Hz, 2H), 5.42(s, 1H), 4.74 (s, 1H), 4.62 (t, J = 11.9 Hz, 1H), 4.30 (s, 2H), 3.96 (s, 2H), 3.74 (s, 1H), 3.49 (s, 2H), 3.33 (d, J = 4.5 Hz, 2H), 3.17 (s, 4H), 2.11 (s,2H), 1.88 (d, J = 11.7 Hz, 2H), 1.74 (s, 3H), 1.36 (dd, J = 23.7, 11.5 Hz, 2H),1.23 (dd, J= 24.6, 13.5 Hz, 2H), 1.17 (t, J = 7.2 Hz, 3H);
[0174] The carbon NMR data for compound I-12 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.8, 165.1,163.1, 160.6, 158.2, 155.6 (d, J = 159.4 Hz), 150.5, 145.6, 134.5 (d, J = 3.3Hz), 133.8, 131.7 (d, J = 4.3 Hz), 131.0, 129.7, 129.4 (d, J = 3.6 Hz), 128.5,127.3, 125.2, 124.1 (d, J = 18.7 Hz), 116.6, 116.3 (d, J = 22.0 Hz), 49.3, 49.0,47.0, 42.1, 37.8, 36.3, 32.0, 29.9, 23.6, 15.0;
[0175] The NMR fluorine spectrum data of compound I-12 are as follows: 19 F NMR (471 MHz, CDCl3) δ -60.85, -117.50.
[0176] Example 13
[0177] N-((1r,4r)-4-((4-(ethylamino)-5-fluoropyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide (compound I-13)
[0178]
[0179] Using intermediate 3 and 2-chloro-N-ethyl-5-fluoropyrimidin-4-amine as raw materials, the same method as that used in Example 1 was employed to prepare I-1.
[0180] White solid, yield 68%;
[0181] The 1H NMR spectrum data of compound I-13 are as follows: 1H NMR (500 MHz, CDCl3) δ 11.07 (s, 1H),8.46 (d, J = 7.1 Hz, 1H), 7.81 – 7.69 (m, 3H), 7.59 – 7.29 (m, 2H), 7.04 (t, J =8.7 Hz, 1H), 6.90 (dd, J = 27.5, 8.7 Hz, 4H), 5.81 (dd, J = 59.2, 8.2 Hz, 1H), 4.78 – 4.49 (m, 2H), 4.29 (s, 2H), 3.94 (s, 2H), 3.73 – 3.36 (m, 3H), 3.30 (s, 2H), 3.15 (s, 2H), 1.92 (d, J = 15.9 Hz, 8H), 1.80 (d, J = 9.7 Hz, 2H), 1.73(s, 3H), 1.42 – 1.03 (m, 4H);
[0182] The carbon NMR data for compound I-13 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.9, 169.6,165.1, 160.7, 157.2 (d, J = 247.7 Hz), 150.6, 145.7, 134.4 (d, J = 3.3 Hz),133.8, 131.7, 131.3 (d, J = 3.2 Hz), 130.8, 129.7, 129.4 (d, J = 3.4 Hz), 128.4,127.3, 125.2, 124.0 (d, J = 18.0 Hz), 116.7, 116.3 (d, J = 21.7 Hz), 52.6, 49.4,49.0, 47.6, 46.9, 46.4, 42.0, 37.8, 32.1, 29.8, 23.5;
[0183] The NMR fluorine spectrum data of compound I-13 are as follows: 19 F NMR (471 MHz, CDCl3) δ -117.50, -117.58.
[0184] Example 14
[0185] N-(4-(N-((1r,4r)-4-((5-chloro-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-14)
[0186]
[0187] (1) Step 1: tert-butyl((1r,4r)-4-((4-(2,2,2-trifluoroacetamido)phenyl)amino)cyclohexyl)carbamate (intermediate 4)
[0188]
[0189] 2,2,2-trifluoro-N-(4-iodophenyl)acetamide (3.1494 g, 10 mmol), trans-(4-aminocyclohexyl)carbamate tert-butyl ester (3.2145 g, 15 mmol), cuprous iodide (0.1905 g, 1 mmol), D-proline (0.4606 g, 4 mmol), N-methylglycine (0.3564 g, 4 mmol), and potassium phosphate (4.2454 g, 20 mmol) were added to 20 mL of dry DMSO. The mixture was purged with nitrogen three times and stirred at 100 °C for 16 hours under nitrogen protection. The reaction was monitored by TLC until the reaction was complete. The mixture was then extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, mixed with silica gel, and subjected to column chromatography to obtain 1.6850 g of white solid, with a yield of 42%.
[0190] The 1H NMR spectrum data of intermediate 4 are as follows: 1 H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 16.2 Hz, 1H), 7.32 (d, J = 8.8 Hz, 2H), 6.56 (dd, J = 8.7, 1.5 Hz, 2H), 4.41 (s, 1H), 3.60 (s, 1H), 3.46 (s, 1H), 3.21 (dd, J = 8.6, 5.0 Hz, 1H), 2.09 (dd, J = 38.8, 7.9Hz, 4H), 1.45 (s, 9H), 1.30 – 1.14 (m, 4H);
[0191] (2) Step 2: tert-butyl ((1r,4r)-4-(N-(4-(2,2,2-trifluoroacetamido)phenyl)acetamido)cyclohexyl)carbamate (intermediate 5)
[0192]
[0193] Accurately weigh intermediate 4 (4.0119 g, 10 mmol) into a 50 mL round-bottom flask, add 60 mL of dry tetrahydrofuran, and add 4.0 mL (20 mmol) of DIPEA to the system using a 50 mL disposable syringe. Then, accurately add 1.0 mL (10 mmol) of acetyl chloride dropwise to the system using a 10 mL disposable syringe. React at 0 °C for 1 hour. After the reaction is complete, pour 10 mL of cold water into the reaction solution, add 3 x 30 mL of ethyl acetate for extraction three times, combine the organic phases, wash successively with water and saturated brine, dry the organic phase with anhydrous sodium sulfate, remove the solvent under vacuum, and obtain 2.2160 g of white solid by column chromatography, with a yield of 50%.
[0194] The 1H NMR spectrum data of intermediate 5 are as follows: 1 H NMR (500 MHz, CDCl3) δ 8.47 (s, 1H), 7.71(d, J = 8.6 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 4.62 (ddd, J = 12.0, 8.6, 3.6 Hz,1H), 4.39 (s, 1H), 3.18 (s, 1H), 2.01 (d, J = 11.6 Hz, 2H), 1.86 (d, J = 11.6 Hz, 2H), 1.76 (s, 3H), 1.43 (s, 9H), 1.34 – 1.23 (m, 2H), 1.23 – 1.07 (m, 2H);
[0195] (3) Step 3: tert-butyl ((1r,4r)-4-(N-(4-(2-fluoro-5-(4-oxo-3,4-dihydrobenzothiazol-1-ylmethyl)anilino)phenyl)acetamido))carboxylic acid ester (intermediate 6)
[0196]
[0197] Take intermediate 5 (4.4320 g, 10 mmol) and potassium carbonate (7.1869 g, 52 mmol) into a 50 mL round-bottom flask, and add 20 mL of [unclear text - possibly a typo, should be "20 mL"]. A methanol solution was heated and stirred in an oil bath at 65°C for 2 hours. The reaction solution was then cooled and extracted three times with 3 x 20 mL of dichloromethane. The organic phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the solvent was removed under vacuum to obtain a white solid. Then, 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid (3.5792 g, 12 mmol), HATU (4.1825 g, 11 mmol), and triethylamine (2.11 mL, 15 mmol) were added, followed by 15 mL of dry DMF. The reaction was carried out at room temperature for 16 hours. After the reaction was complete, 15 mL of cold water was added to the reaction solution, and the mixture was stirred for 1 hour. The mixture was filtered, and the filter cake was collected. The filter cake was washed three times with 3 x 10 mL of ethyl acetate, and then three times with 3 x 10 mL of water to obtain 4.3910 g of white solid, with a yield of 70%.
[0198] The 1H NMR spectrum data of intermediate 6 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.24 (s, 1H), 8.55(d, J = 15.8 Hz, 1H), 8.46 (d, J = 7.5 Hz, 1H), 8.16 (d, J = 5.9 Hz, 1H), 7.80 –7.73 (m, 3H), 7.71 (d, J = 8.5 Hz, 2H), 7.44 (s, 1H), 7.14 (dd, J = 11.6, 8.6 Hz, 1H), 7.07 (d, J = 8.3 Hz, 2H), 4.59 (t, J = 11.8 Hz, 1H), 4.35 (s, 2H), 3.39 (s,1H), 3.18 (s, 1H), 1.99 (d, J = 10.0 Hz, 4H), 1.75 (s, 3H), 1.40 (s, 9H), 1.28– 1.15 (m, 4H);
[0199] (4) Step 4: Preparation of compound I-14
[0200]
[0201] Add 2 mL of dioxane hydrochloride solution to intermediate 6 (0.0627 g, 0.1 mmol), stir at room temperature for 2 h, and monitor the reaction progress by TLC until Boc is completely removed. Add anhydrous diethyl ether to the reaction solution, sonicate, pour off the liquid, wash twice with anhydrous diethyl ether, and remove the solvent under vacuum. Then add 2,5-dichloro-N-(3-chlorophenyl)pyrimidin-4-amine (0.0627 g, 0.12 mmol), DIPEA (0.11 mL, 0.6 mmol), and 2 mL of dry NMP. Purify the solution with nitrogen three times, stir at 100 °C for 15 h under nitrogen protection, and monitor the reaction end by TLC. Extract with ethyl acetate, wash with saturated brine, dry with anhydrous sodium sulfate, concentrate under reduced pressure, mix with silica gel, and column chromatography to obtain 0.0397 g of white solid, with a yield of 52%.
[0202] The 1H NMR spectrum data of compound I-14 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.56 (s, 1H),8.60 (d, J = 15.5 Hz, 1H), 8.47 (dd, J = 6.0, 3.7 Hz, 1H), 8.17 (dd, J = 7.3, 2.1Hz, 1H), 7.91 (s, 1H), 7.85 – 7.67 (m, 5H), 7.54 – 7.39 (m, 1H), 7.20 – 7.07(m, 4H), 7.01 (s, 2H), 4.83 – 4.54 (m, 1H), 4.36 (s, 2H), 3.50 (dd, J = 7.5, 3.6 Hz, 1H), 2.14 (d, J = 10.0 Hz, 2H), 1.91 (d, J = 11.2 Hz, 2H), 1.77 (s, 3H), 1.48 – 1.30 (m, 4H);
[0203] The carbon NMR data for compound I-14 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.5, 161.4,160.5, 159.0 (d, J = 118.8 Hz), 155.4, 154.3, 145.6, 139.7, 137.9, 135.8,134.8, 134.8, 134.6, 134.2 (d, J= 8.8 Hz), 133.8, 131.0, 129.7 (d, J = 14.0 Hz),128.5, 127.4, 121.4 (d, J = 11.4 Hz), 121.2, 116.9 (d, J = 25.3 Hz), 53.0, 37.9,32.1, 30.0, 23.6;
[0204] The NMR fluorine spectrum data of compound I-14 are as follows: 19 F NMR (471 MHz, CDCl3) δ -115.77.
[0205] Example 15
[0206] N-(4-(N-((1r,4r)-4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-15)
[0207]
[0208] Using intermediate 6 and 2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidin-4-amine as raw materials, the procedure was the same as that used in Example 14 to prepare I-14;
[0209] White solid, yield 50%;
[0210] The 1H NMR spectrum data of compound I-15 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.10 (s, 1H), 9.52 (s, 1H), 8.61 – 8.52 (m, 2H), 8.47 (d, J = 7.8 Hz, 1H), 8.17 (dd, J = 7.4,2.0 Hz, 1H), 7.96 (s, 1H), 7.88 – 7.72 (m, 6H), 7.46 (d, J = 3.0 Hz, 1H), 7.21– 7.08 (m, 4H), 4.71 – 4.62 (m, 1H), 4.36 (s, 2H), 3.47 (s, 1H), 3.20 (hept, J= 7.0 Hz, 1H), 2.11 (d, J = 11.4 Hz, 2H), 1.92 (d, J = 11.3 Hz, 2H), 1.78 (s,3H), 1.45 – 1.35 (m, 2H), 1.26 (dd, J = 18.6, 9.2 Hz, 9H);
[0211] The carbon NMR data for compound I-15 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.4, 160.5,159.0 (d, J = 117.1 Hz), 155.4, 145.6, 138.8, 137.9, 134.3 (d, J = 5.3 Hz),133.84, 132.2, 131.1 (d, J = 48.3 Hz), 129.6, 128.5, 127.4, 125.0, 123.0 (d, J =8.3 Hz), 121.17, 116.9 (d, J = 25.2 Hz), 55.7, 52.9, 37.9, 321, 30.1, 29.8,23.6, 22.8, 15.5, 14.5;
[0212] The NMR fluorine spectrum data of compound I-15 are as follows: 19 F NMR (471 MHz, CDCl3) δ -115.82.
[0213] Example 16
[0214] N-(4-(N-((1r,4r)-4-((4-((3-bromophenyl)amino)-5-chloropyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-16)
[0215]
[0216] Using intermediate 6 and N-(3-bromophenyl)-2,5-dichloropyrimidin-4-amine as raw materials, the same method as that used in Example 14 was employed to prepare I-14.
[0217] White solid, yield 53%;
[0218] The 1H NMR spectrum data of compound I-16 are as follows: 1 H NMR (500 MHz, DMSO- d 6) δ 10.60 (s, 1H),8.64 (s, 1H), 8.27 (d, J = 7.8 Hz, 1H), 8.16 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.91 (dd, J = 18.1, 10.8 Hz, 1H), 7.86 – 7.76 (m, 2H), 7.64 (d, J = 5.7 Hz, 3H),7.53 (s, 2H), 7.31 (t, J = 9.1 Hz, 1H), 7.18 (d, J = 8.4 Hz, 2H), 7.01 (d, J = 8.5Hz, 3H), 4.41 (d, J = 30.4 Hz, 3H), 3.52 (s, 1H), 1.89 (d, J = 10.7 Hz, 2H), 1.77(d, J = 10.1 Hz, 2H), 1.64 (s, 3H), 1.37 (dd, J = 23.8, 11.7 Hz, 2H), 1.20 (d, J =14.7 Hz, 2H);
[0219] The carbon NMR data for compound I-16 are as follows: 13 C NMR (126 MHz, DMSO- d 6) δ 174.3, 168.9,162.9, 159.5, 157.7 (d, J = 246.4 Hz), 155.5, 155.2, 145.0, 140.9, 134.6 (d, J =3.3 Hz), 133.6, 131.7 (d, J = 6.6 Hz), 130.8, 129.9, 129.1, 128.0 (d, J = 2.5Hz), 126.2, 125.6, 123.3 (d, J= 5.0 Hz), 121.1, 120.0, 116.4 (d, J = 23.3 Hz),36.5, 31.3, 29.8, 23.2;
[0220] The NMR fluorine spectrum data of compound I-16 are as follows: 19 F NMR (471 MHz, DMSO- d 6) δ -117.80.
[0221] Example 17
[0222] N-(4-(N-((1r,4r)-4-((5-chloro-4-(4-fluorophenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-17)
[0223]
[0224] Using intermediate 6 and 2,5-dichloro-4-(4-fluorophenyl)pyrimidine as raw materials, the procedure was the same as that used in Example 14 to prepare I-14;
[0225] White solid, yield 65%;
[0226] The 1H NMR spectrum data of compound I-17 are as follows: 1 H NMR (500 MHz, CDCl3) δ 11.18 (s, 1H),8.65 (d, J = 14.9 Hz, 1H), 8.46 (d, J = 7.6 Hz, 1H), 8.22 (s, 1H), 8.13 (d, J = 5.7Hz, 1H), 7.88 – 7.60 (m, 7H), 7.63 – 7.34 (m, 1H), 7.22 – 6.94 (m, 5H), 5.31(d, J = 7.0 Hz, 1H), 4.65 (t, J = 11.9 Hz, 1H), 4.35 (s, 2H), 3.56 (dd, J = 7.5,3.6 Hz, 1H), 2.23 – 2.00 (m, 2H), 1.89 (d, J= 14.5 Hz, 2H), 1.75 (s, 3H), 1.39(dd, J = 23.8, 11.2 Hz, 2H), 1.26 (q, J = 11.6 Hz, 2H);
[0227] The carbon NMR data for compound I-17 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.4, 163.8 (d, J = 250.4 Hz), 160.4 (d, J = 75.0 Hz), 145.6, 137.9, 135.8, 134.8 (d, J = 2.8 Hz), 134.2 (d, J = 9.2 Hz), 133.8, 132.2, 131.7, 131.4 (d, J = 8.5 Hz), 130.9, 129.0 (d, J = 147.7 Hz), 127.3, 125.1, 121.2, 116.8 (d, J = 25.2 Hz), 116.2, 115.3 (d, J = 21.7 Hz), 53.0, 49.6, 37.9, 32.1, 29.9, 23.6;
[0228] The NMR fluorine spectrum data of compound I-17 are as follows: 19 F NMR (471 MHz, CDCl3) δ -110.57, -115.79.
[0229] Example 18
[0230] N-(4-(N-((1r,4r)-4-((5-chloro-4-(4-methoxyphenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-18)
[0231]
[0232] Using intermediate 6 and 2,5-dichloro-4-(4-methoxyphenyl)pyrimidine as raw materials, the same method as that used in Example 14 was employed to prepare I-14.
[0233] White solid, yield 45%;
[0234] The 1H NMR spectrum data of compound I-18 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.63 (s, 1H),8.58 (d, J = 15.5 Hz, 1H), 8.47 (d, J = 7.2 Hz, 1H), 8.26 – 8.06 (m, 2H), 7.82 –7.65 (m, 7H), 7.44 (s, 1H), 7.19 – 7.06 (m, 3H), 6.95 (d, J = 8.6 Hz, 2H), 5.12(d, J = 7.9 Hz, 1H), 4.66 (t, J = 11.8 Hz, 1H), 4.35 (s, 2H), 3.84 (s, 3H), 3.57(d, J = 7.4 Hz, 1H), 2.14 (d, J = 10.6 Hz, 2H), 1.89 (d, J = 10.8 Hz, 2H), 1.76 (s,3H), 1.39 (dd, J = 23.4, 11.1 Hz, 2H), 1.32 – 1.21 (m, 2H);
[0235] The carbon NMR data for compound I-18 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.4, 161.1,160.4, 160.1, 158.4 (d, J = 30.4 Hz), 145.6, 137.8, 135.9, 134.8, 134.2 (d, J =9.3 Hz), 133.8, 132.1 (d, J = 71.1 Hz), 131.0, 129.7, 128.5, 127.4, 125.1,121.2 (d, J = 10.4 Hz), 116.9 (d, J = 25.3 Hz), 113.6, 55.5, 53.0, 49.6, 37.9,32.2, 30.0, 23.6;
[0236] The NMR fluorine spectrum data of compound I-18 are as follows: 19 F NMR (471 MHz, CDCl3) δ -115.77.
[0237] Example 19
[0238] N-(4-(N-((1r,4r)-4-((5-chloro-4-((3-fluorophenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-19)
[0239]
[0240] Using intermediate 6 and 2,5-dichloro-N-(3-fluorophenyl)pyrimidin-4-amine as raw materials, the same method as that used in Example 14 was employed to prepare I-14.
[0241] White solid, yield 54%;
[0242] The 1H NMR spectrum data of compound I-19 are as follows: 1 H NMR (500 MHz, DMSO- d 6) δ 12.61 (s, 1H),10.62 (s, 1H), 8.65 (d, J = 61.8 Hz, 1H), 8.27 (dd, J = 7.9, 1.0 Hz, 1H), 8.01(d, J = 8.0 Hz, 1H), 7.97 – 7.76 (m, 5H), 7.69 – 7.42 (m, 4H), 7.30 (t, J = 9.1Hz, 1H), 7.18 (d, J = 8.6 Hz, 2H), 7.07 – 6.65 (m, 3H), 4.40 (d, J = 26.1 Hz,3H), 3.26 (s, 1H), 1.90 (d, J = 10.9 Hz, 2H), 1.78 (d, J = 10.6 Hz, 2H), 1.66 (s, 3H), 1.35 (d, J = 11.7 Hz, 2H), 1.10 (dd, J = 23.4, 11.8 Hz, 2H);
[0243] The carbon NMR data for compound I-19 are as follows: 13 C NMR (126 MHz, DMSO- d 6) δ 168.9, 162.9,159.5, 157.7 (d, J = 247.7 Hz), 155.3, 145.0, 141.1, 141.0, 141.0, 138.6,134.7, 133.6, 132.8 (d, J = 8.2 Hz), 131.7, 130.6, 129.9 (d, J = 2.1 Hz), 129.1,128.0, 126.2, 125.6, 124.8 (d, J = 15.8 Hz), 120.1, 117.2, 116.4 (d, J = 22.3Hz), 52.2, 50.0, 36.5, 31.1, 29.7, 23.3;
[0244] The NMR fluorine spectrum data of compound I-19 are as follows: 19 F NMR (471 MHz, DMSO- d 6) δ -112.38, -118.00.
[0245] Example 20
[0246] N-(4-(N-((1r,4r)-4-((4-((3-acetamidophenyl)amino)-5-chloropyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-20)
[0247]
[0248] Using intermediate 6 and N-(3-((2,5-dichloropyrimidin-4-yl)amino)phenyl)acetamide as raw materials, the same method as that used in Example 14 was employed to prepare I-14.
[0249] White solid, yield 45%;
[0250] The 1H NMR spectrum data of compound I-20 are as follows: 1 H NMR (500 MHz, DMSO- d6) δ 12.61 (s, 1H),10.58 (s, 1H), 9.83 (d, J = 35.8 Hz, 1H), 8.53 (s, 1H), 8.27 (d, J = 7.7 Hz, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.94 – 7.62 (m, 7H), 7.52 (s, 1H), 7.36 – 7.25 (m,2H), 7.17 (d, J = 7.9 Hz, 3H), 7.08 – 6.34 (m, 2H), 4.38 (s, 3H), 3.25 (s, 1H), 1.93 (dd, J = 50.9, 27.8 Hz, 5H), 1.74 (d, J = 8.4 Hz, 2H), 1.64 (s, 3H), 1.31 (s, 2H), 1.04 (s, 2H);
[0251] The carbon NMR data for compound I-20 are as follows: 13 C NMR (126 MHz, DMSO- d 6) δ 168.8, 168.2,165.6, 162.9, 159.5, 156.7, 134.6 (d, J = 2.9 Hz), 133.6, 132.8 (d, J = 9.0 Hz),131.6, 130.5, 130.0 (d, J = 3.3 Hz), 129.1, 127.9, 126.1, 125.6, 124.8 (d, J =14.8 Hz), 120.2, 116.3 (d, J = 22.3 Hz), 52.5, 49.4, 36.5, 31.3, 29.7, 24.0,23.2;
[0252] The NMR fluorine spectrum data of compound I-20 are as follows: 19 F NMR (471 MHz, DMSO- d 6) δ -117.81.
[0253] Example 21
[0254] 2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)-N-(4-(N-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)acetamyl)phenyl)benzamide (compound I-21)
[0255]
[0256] Using intermediate 6 and 2-chloroquinazoline as raw materials, the same method as that used in Example 14 was employed to prepare I-14.
[0257] White solid, yield 55%;
[0258] The 1H NMR spectrum data of compound I-21 are as follows: 1 H NMR (500 MHz, DMSO- d 6) δ 12.62 (s, 1H), 10.59 (s, 1H), 9.04 (s, 1H), 8.27 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.90 (t, J = 7.4 Hz, 1H), 7.86 – 7.70 (m, 4H), 7.67 – 7.58 (m, 2H), 7.53 (s,1H), 7.40 (d, J = 8.4 Hz, 1H), 7.33 – 7.13 (m, 5H), 4.45 (t, J = 11.8 Hz, 1H), 4.37 (s, 2H), 3.61 (d, J = 7.8 Hz, 1H), 1.98 (d, J = 8.4 Hz, 2H), 1.80 (d, J = 11.0Hz, 2H), 1.65 (s, 3H), 1.42 (dd, J = 24.0, 11.5 Hz, 2H), 1.28 – 1.05 (m, 2H);
[0259] The carbon NMR data for compound I-21 are as follows: 13 C NMR (126 MHz, DMSO- d 6) δ 168.9, 162.9,162.1, 159.5, 157.7 (d, J= 247.6 Hz), 145.0, 138.6, 134.8, 134.6 (d, J = 3.5Hz), 134.1, 133.6, 132.8 (d, J = 7.7 Hz), 131.7, 130.6, 129.9, 129.1, 127.9 (d, J = 7.0 Hz), 126.2, 125.6, 124.8 (d, J = 15.4 Hz), 121.8, 120.2, 119.6, 116.4(d, J = 22.0 Hz), 52.5, 48.6, 36.5, 31.2, 29.8, 23.3;
[0260] The NMR fluorine spectrum data of compound I-21 are as follows: 19 F NMR (471 MHz, DMSO- d 6) δ -117.92.
[0261] Example 22
[0262] N-(3-(N-((1r,4r)-4-((5-chloropyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-22)
[0263]
[0264] (1) Step 1: tert-butyl((1r,4r)-4-((3-(2,2,2-trifluoroacetamido)phenyl)amino)cyclohexyl)carbamate (intermediate 7)
[0265]
[0266] 2,2,2-trifluoro-N-(3-iodophenyl)acetamide (3.1494 g, 10 mmol), trans-(4-aminocyclohexyl)carbamate tert-butyl ester (3.2145 g, 15 mmol), cuprous iodide (0.1905 g, 1 mmol), D-proline (0.1152 g, 1 mmol), and potassium phosphate (4.2454 g, 20 mmol) were added to 20 mL of dry DMSO. The mixture was purged with nitrogen three times and stirred at 100 °C for 14 hours under nitrogen protection. The reaction was monitored by TLC until the reaction was complete. The mixture was then extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, mixed with silica gel, and subjected to column chromatography to obtain 1.6048 g of white solid, with a yield of 40%.
[0267] The 1H NMR spectrum of intermediate 7 is as follows: 1 H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H), 7.13(t, J = 8.1 Hz, 1H), 7.01 (s, 1H), 6.68 – 6.59 (m, 1H), 6.43 (dd, J = 8.2, 1.7Hz, 1H), 4.39 (s, 1H), 3.46 (s, 1H), 3.22 (s, 1H), 2.14 (d, J = 7.3 Hz, 2H), 2.06 (d, J = 3.7 Hz, 2H), 1.44 (d, J = 4.4 Hz, 10H), 1.28 – 1.21 (m, 4H);
[0268] (2) Step 2: tert-butyl ((1r,4r)-4-(N-(3-(2,2,2-trifluoroacetamido)phenyl)acetamido)cyclohexyl)carbamate (intermediate 8)
[0269]
[0270] Accurately weigh intermediate 7 (4.0119 g, 10 mmol) into a 50 mL round-bottom flask, add 60 mL of dry tetrahydrofuran, and add 4.0 mL (20 mmol) of DIPEA to the system using a 50 mL disposable syringe. Then, accurately add 1.0 mL (10 mmol) of acetyl chloride dropwise to the system using a 10 mL disposable syringe. React at 0 °C for 1 hour. After the reaction is complete, pour 10 mL of cold water into the reaction solution, add 3 x 30 mL of ethyl acetate for extraction three times, combine the organic phases, wash successively with water and saturated brine, dry the organic phase with anhydrous sodium sulfate, remove the solvent under vacuum, and obtain 1.9944 g of white solid by column chromatography, with a yield of 45%.
[0271] The 1H NMR spectrum of intermediate 8 is as follows: 1 H NMR (500 MHz, CDCl3) δ 8.93 (s, 1H), 7.72(d, J = 7.8 Hz, 1H), 7.47 (dd, J = 16.5, 8.5 Hz, 2H), 6.97 (d, J = 7.6 Hz, 1H), 4.62 (dd, J = 16.1, 7.7 Hz, 1H), 4.47 (d, J = 6.2 Hz, 1H), 3.17 (s, 1H), 1.98 (d, J = 11.5 Hz, 2H), 1.86 (d, J = 11.4 Hz, 2H), 1.78 (s, 3H), 1.42 (s, 9H), 1.35 –1.23 (m, 2H), 1.19 (s, 2H);
[0272] (3) Step 3: tert-butyl ((1r,4r)-4-(N-(3-(2-fluoro-5-(4-oxo-3,4-dihydrobenzothiazol-1-ylmethyl)aniline)phenyl)acetamido))carboxylic acid ester (intermediate 9)
[0273]
[0274] Take intermediate 8 (4.4320 g, 10 mmol) and potassium carbonate (7.1869 g, 52 mmol) into a 50 mL round-bottom flask, and add 20 mL of [unclear text - possibly a typo, should be "20 mL"]. A methanol solution was heated and stirred in an oil bath at 65°C for 2 hours. The reaction solution was then cooled and extracted three times with 3 x 20 mL of dichloromethane. The organic phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the solvent was removed under vacuum to obtain a white solid. Then, 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid (3.5792 g, 12 mmol), HATU (4.1825 g, 11 mmol), and triethylamine (2.11 mL, 15 mmol) were added, followed by 15 mL of dry DMF. The reaction was carried out at room temperature for 16 hours. After the reaction was complete, 15 mL of cold water was added to the reaction solution, and the mixture was stirred for 1 hour. The mixture was filtered, and the filter cake was collected. The filter cake was washed three times with 3 x 10 mL of ethyl acetate, and then three times with 3 x 10 mL of water to obtain 3.1365 g of white solid, with a yield of 50%.
[0275] The 1H NMR spectrum of intermediate 9 is as follows: 1 H NMR (500 MHz, CDCl3) δ 10.19 (s, 1H), 8.54(d, J = 15.9 Hz, 1H), 8.46 (dd, J = 7.9, 1.5 Hz, 1H), 8.16 (dd, J = 7.4, 2.1 Hz,1H), 7.84 – 7.70 (m, 3H), 7.66 (s, 1H), 7.54 – 7.35 (m, 3H), 7.14 (dd, J =11.8, 8.5 Hz, 1H), 6.88 (d, J = 7.6 Hz, 1H), 4.60 (s, 1H), 4.37 (s, 1H), 4.34(s, 2H), 3.19 (s, 1H), 1.88 (s, 2H), 1.79 (s, 3H), 1.62 (s, 2H), 1.40 (s,9H), 1.35 – 1.10 (m, 4H);
[0276] (4) Step 4: Preparation of compound I-22
[0277]
[0278] Add 2 mL of dioxane hydrochloride solution to intermediate 9 (0.0627 g, 0.1 mmol), stir at room temperature for 2 h, and monitor the reaction progress by TLC until Boc is completely removed. Add anhydrous diethyl ether to the reaction solution, sonicate, pour off the liquid, wash twice with anhydrous diethyl ether, and remove the solvent under vacuum. Then add 2,5-dichloropyrimidine (0.0179 g, 0.12 mmol), DIPEA (0.11 mL, 0.6 mmol), and 2 mL of dry NMP. Purify with nitrogen three times, stir at 150 °C for 18 h under nitrogen protection, and monitor the reaction end by TLC. Extract with ethyl acetate, wash with saturated brine, dry with anhydrous sodium sulfate, concentrate under reduced pressure, mix with silica gel, and column chromatography to obtain 0.0364 g of white solid, with a yield of 57%.
[0279] The 1H NMR spectrum data of compound I-22 are as follows: 1 H NMR (500 MHz, DMSO- d 6) δ 12.61 (s, 1H), 10.55 (s, 1H), 8.31 – 8.21 (m, 3H), 7.99 (d, J = 8.0 Hz, 1H), 7.89 (t, J = 7.4Hz, 1H), 7.82 (t, J = 7.5 Hz, 1H), 7.69 (dd, J = 21.1, 6.6 Hz, 2H), 7.61 (s, 1H),7.56 – 7.48 (m, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.36 – 7.25 (m, 2H), 6.96 (d, J =7.6 Hz, 1H), 4.43 (t, J = 11.7 Hz, 1H), 4.36 (s, 2H), 3.49 (d, J = 5.3 Hz, 1H), 1.89 (d, J = 9.2 Hz, 2H), 1.76 (s, 2H), 1.67 (s, 3H), 1.38 (dd, J = 23.5, 11.3Hz, 2H), 1.26 – 0.98 (m, 2H);
[0280] The carbon NMR data for compound I-22 are as follows: 13 C NMR (126 MHz, DMSO- d6) δ 168.6, 162.9,160.0, 159.5, 157.7 (d, J = 248.1 Hz), 145.0, 139.7, 139.5, 134.6 (d, J = 3.1Hz), 133.6, 132.9 (d, J = 8.3 Hz), 131.6, 130.0, 129.6, 129.1, 128.0, 126.1,125.6, 125.6, 124.6 (d, J = 15.3 Hz), 121.1, 119.4, 116.8, 116.3 (d, J = 22.3Hz), 79.2, 52.6, 49.1, 36.5, 31.1, 29.7, 23.2;
[0281] The NMR fluorine spectrum data of compound I-22 are as follows: The NMR 1H spectrum data of compound I-22 are as follows: 19 F NMR (471MHz, DMSO- d 6) δ -117.64.
[0282] Example 23
[0283] N-(3-(N-((1r,4r)-4-((5-cyanopyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-23)
[0284]
[0285] Using intermediate 9 and 2-chloro-5-cyanopyrimidine as raw materials, the same method as that used in Example 22 was employed to prepare I-22.
[0286] White solid, yield 62%;
[0287] The 1H NMR spectrum data of compound I-23 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.22 (s, 1H),8.56 (d, J = 16.0 Hz, 1H), 8.50 – 8.39 (m, 1H), 8.28 (d, J = 2.0 Hz, 1H), 8.14(dd, J= 7.3, 2.1 Hz, 1H), 7.76 (dddd, J = 11.7, 7.3, 6.6, 4.9 Hz, 1H), 7.53 –7.36 (m, 1H), 7.16 (dd, J = 11.8, 8.5 Hz, 1H), 6.91 (d, J = 8.3 Hz, 1H), 6.29 (d, J = 8.8 Hz, 1H), 4.95 (d, J = 6.4 Hz, 1H), 4.76 – 4.60 (m, 1H), 4.34 (s, 2H), 3.59 – 3.43 (m, 1H), 2.11 (d, J = 9.5 Hz, 2H), 1.95 (d, J = 18.4 Hz, 2H), 1.80(s, 3H), 1.39 (t, J = 11.8 Hz, 4H);
[0288] The carbon NMR data for compound I-23 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.3, 161.6,160.8, 160.4, 158.8 (d, J = 92.2 Hz), 153.3, 145.7, 140.1, 139.39, 138.9,134.8, 134.2 (d, J = 9.3 Hz), 133.8, 131.9 (d, J = 39.1 Hz), 129.7 (d, J = 32.3Hz), 128.4, 127.3, 126.3, 125.0, 122.3, 121.3 (d, J = 11.6 Hz), 118.9, 116.8 (d, J = 25.1 Hz), 96.3, 53.0, 49.4, 37.9, 32.1, 29.8, 23.6;
[0289] The NMR fluorine spectrum data of compound I-23 are as follows: 19 F NMR (471 MHz, CDCl3) δ -115.68 (s).
[0290] Example 24
[0291] N-(3-(N-((1r,4r)-4-((5-chloro-4-(4-methoxyphenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-24)
[0292]
[0293] Using intermediate 9 and 2,5-dichloro-4-(4-methoxyphenyl)pyrimidine as raw materials, the same method as that used in Example 22 was employed to prepare I-22.
[0294] White solid, yield 48%;
[0295] The 1H NMR spectrum data of compound I-24 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.07 (s, 1H),8.54 (d, J = 16.0 Hz, 1H), 8.49 – 8.42 (m, 1H), 8.19 (s, 1H), 8.16 (dd, J = 7.4,2.0 Hz, 1H), 7.85 – 7.70 (m, 5H), 7.66 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.48– 7.38 (m, 2H), 7.15 (dd, J = 11.8, 8.5 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.91(d, J = 7.8 Hz, 1H), 5.05 (d, J = 6.5 Hz, 1H), 4.68 (t, J = 11.5 Hz, 1H), 4.34 (s,2H), 3.84 (s, 3H), 3.59 (s, 1H), 2.15 (d, J = 11.1 Hz, 2H), 1.93 (s, 2H), 1.80 (s, 3H), 1.44 – 1.26 (m, 4H);
[0296] The carbon NMR data of compound I-24 are as follows: 13C NMR (126 MHz, CDCl3) δ 170.3, 161.1,160.6, 160.1, 158.4 (d, J = 33.7 Hz), 145.7, 140.3, 138.8, 134.9 (d, J = 3.2 Hz), 134.2 (d, J = 9.2 Hz), 133.8, 132.2, 131.8 (d, J = 18.2 Hz), 130.9, 129.7 (d, J =29.5 Hz), 128.5, 127.3, 126.5, 125.1, 122.4, 121.2 (d, J = 11.8 Hz), 120.3, 116.9 (d, J = 25.5 Hz), 116.2, 113.6, 55.5, 53.2, 49.5, 37.9, 32.2, 29.9, 23.6;
[0297] The NMR fluorine spectrum data of compound I-24 are as follows: 19 F NMR (471 MHz, CDCl3) δ -115.63.
[0298] Example 25
[0299] N-(3-(N-((1r,4r)-4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide (compound I-25)
[0300]
[0301] Using intermediate 9 and 2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidin-4-amine as raw materials, the procedure was the same as that used in Example 22 to prepare I-22;
[0302] White solid, yield 52%;
[0303] The 1H NMR spectrum data of compound I-25 are as follows: 1 H NMR (500 MHz, CDCl3) δ 10.83 (s, 1H), 9.49 (s, 1H), 8.65 (d, J= 14.4 Hz, 1H), 8.56 (d, J = 8.4 Hz, 1H), 8.45 (dd, J =5.7, 2.9 Hz, 1H), 8.17 – 8.07 (m, 1H), 7.90 (d, J = 60.6 Hz, 1H), 7.85 – 7.64(m, 5H), 7.49 (dd, J = 36.9, 5.6 Hz, 1H), 7.51 – 7.37 (m, 2H), 7.15 (dd, J =11.6, 8.6 Hz, 1H), 6.91 (d, J = 7.5 Hz, 1H), 4.68 (d, J = 11.4 Hz, 1H), 4.34 (s,2H), 3.48 (s, 1H), 3.19 (dt, J = 13.6, 6.8 Hz, 1H), 2.16 (s, 2H), 1.90 (d, J =15.5 Hz, 2H), 1.79 (s, 3H), 1.72 (s, 2H), 1.45 – 1.32 (m, 3H), 1.27 (d, J = 6.8Hz, 8H);
[0304] The carbon NMR data for compound I-25 are as follows: 13 C NMR (126 MHz, CDCl3) δ 170.2 (s),161.5, 160.5 (d, J = 6.7 Hz), 155.4, 145.6, 138.9, 132.2, 131.8, 131.3, 129.7(d, J = 24.6 Hz), 128.5, 127.4, 126.5, 125.0, 124.2, 123.0 (d, J = 32.1 Hz),122.4, 120.2, 116.9 (d, J = 25.2 Hz), 55.6, 53.0, 37.9, 30.1, 23.6, 15.5;
[0305] The NMR fluorine spectrum data of compound I-25 are as follows: 19 F NMR (471 MHz, CDCl3) δ -115.71.
[0306] The prepared compounds were subjected to bioactivity testing, and the specific testing methods are as follows:
[0307] 1. Enzyme activity testing methods
[0308] 1.1 PARP enzyme activity assay method
[0309] The inhibitory effect of the test compounds on PARP1 enzyme activity was determined by ELISA in 96-well plates. Each well was pre-coated with 20 μg / mL histone (diluted in 100 μL PBS buffer, containing 10 mM NaH2PO4, 10 mM Na2HPO4, 150 mM NaCl, pH 7.4) and incubated overnight at 4°C. Each well was then coated with 30 μL of reaction buffer (containing 50 mM Tris, 2 mM MgCl2, pH 8.0) containing 100 μM NAD+, 25 μM biotinylated NAD+, and 200 nM slDNA, followed by 5 μL of different concentrations of the compound or solvent control. The enzymatic reaction was initiated by adding 20 μL of PARP (50 ng / well) and incubating at 30°C for 1 hour. After adding 50 μL of streptavidin-conjugated HRP to the reaction solution, the plate was incubated at 30°C for another 30 minutes. Finally, 100 μL of luminescent substrate solution (0.1 M citrate buffer containing H2O2 and luminol, pH 5.4) was added, and the chemiluminescence signal was measured using a multifunctional spectrophotometer (MolecularDevices SpectraMax M5 microplate reader). The PARP1 enzyme activity inhibition rate was calculated using the formula: (control group luminescence value - treatment group luminescence value) / control group luminescence value × 100%. The half-maximal inhibitory concentration (IC50) for inhibiting PARP1 enzyme activity was calculated using Prism GraphPad software. 50 )value.
[0310] 1.2 CDK12 enzyme activity assay method
[0311] The ATP concentration was 10 μM, and the concentration of the analyte compound was dissolved at room temperature to a concentration of 10 mM. Multiple concentration gradients were achieved using DMSO solution. All enzymatic reactions were performed at 30°C for 40 minutes. A 50 μL reaction system contained 40 mM Tris (pH 7.4), 10 mM MgCl2, 0.1 mg / ml bovine serum albumin, 1 mM dithiothreitol, 10 μM adenosine triphosphate (ATP), 0.2 μg / ml kinase, and 100 μM lipid substrate. After diluting the compound with 10% (v / v) dimethyl sulfoxide (DMSO), 5 μL of the solution was added to the 50 μL reaction system, ensuring a final DMSO concentration of 1% in all reactions. Kinase activity was determined using the Kinase-Glo Plus luminescent kinase assay kit by quantifying the residual ATP content in the solution after the kinase reaction. The luminescent signal generated by the assay was positively correlated with ATP content and negatively correlated with kinase activity. The IC50 value for inhibiting CDK12 enzyme activity was calculated using PrismGraphPad software. 50 value.
[0312] Table 1. Inhibitory activities of compounds on CDK12 and PARP enzyme activities
[0313]
[0314] a The values are repeated independently twice. b ND: Not tested.
[0315] As shown in Table 1, among the compounds prepared in the embodiments of the present invention, I-1, I-2, I-4, I-12, and I-25 have an IC50 value for inhibiting CDK12 enzyme activity. 50 The inhibitory effects of the compounds prepared in the embodiments of this invention are similar to those of the existing CDK12 inhibitor CDK12-IN-2, with compounds I-1 and I-25 showing superior inhibitory effects on CDK12 compared to CDK12-IN-2; compounds I-6 and I-11 exhibit inhibitory effects similar to those of the existing PARP inhibitor olaparib. It can be seen that the compounds prepared in the embodiments of this invention show significant dual inhibitory effects on CDK12 and PARP, with IC50 values for each target site exceeding those of compounds I-1, I-2, and I-22. 50 The values all do not exceed 1.0 μM.
[0316] 2. In vitro cell antiproliferative activity method
[0317] MDA-MB-231 or SK-BR-3 cells were seeded at 3000 cells per well in 96-well plates containing complete culture medium. After overnight seeding, the cells were cultured for 168 h with gradient concentrations (0-10 µM) of the test compound. After treatment, 10 µL of Cell Counting Kit-8 (CCK8 reagent) was added to each well, and incubation was continued for 1-3 h. The absorbance at 450 nm and 650 nm was then measured using a microplate reader, and the absorbance value (A) of each well was calculated as OD450-OD650. The half-maximal inhibitory concentration (IC50) was also determined. 50 The concentration-response curves were fitted using GraphPadPrism 8.0 software for calculation. The data are the average of at least three independent experiments.
[0318] Table 2. Antiproliferative activity of compounds against tumor cells
[0319]
[0320] a The numerical values are repeated 3 times independently. b ND: Not tested.
[0321] As shown in Table 2, the compounds prepared in the embodiments of the present invention have significant anti-proliferation effects on tumor cells. Among them, I-7, I-15, and I-25 have better anti-proliferation effects on tumor cells than the existing CDK-IN-12 and Olaparib.
[0322] In summary, the present invention has the following beneficial effects:
[0323] (1) A single active ingredient can exert a dual inhibitory effect on CDK12 and PARP, reducing the dosage, improving the therapeutic effect, reducing drug resistance, and reducing the toxic side effects of combined drug use;
[0324] (2) It has a significant dual inhibitory effect on CDK12 and PARP, and a significant anti-proliferative effect on tumor cells;
[0325] (3) It has wide applicability, and drugs with it as an active ingredient can be used to treat a variety of cancers or tumors related to CDK12 and / or PARP.
[0326] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.
Claims
1. A CDK12 / PARP dual-target inhibitor, characterized in that, The inhibitor has the chemical structural formula shown in general formula (I): (I), Where A is selected from any of the following structural formulas: , , , , or In these fragments, the nitrogen atom ends are connected to the carbonyl group in the structure of formula (I); Ar is selected from any of the following structural formulas: , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .
2. The CDK12 / PARP dual-target inhibitor according to claim 1, characterized in that, A is selected from any of the following structural formulas: , or .
3. The CDK12 / PARP dual-target inhibitor according to claim 1, characterized in that, Ar is selected from any of the following structural formulas: , , , , , , , , , , , , , , , , , , , or .
4. The CDK12 / PARP dual-target inhibitor according to claim 1, characterized in that, The CDK12 / PARP dual-target inhibitor is selected from any one of the following compounds: I-1: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-nitropyrimidine-2-yl)amino)cyclohexyl)acetamide; I-2: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-(trifluoromethyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide; I-3: N-((1r,4r)-4-((5-cyanopyrimidine-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide; I-4: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)acetamide; I-5: N-((1r,4r)-4-((5-chloropyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide; I-6: N-((1r,4r)-4-((5-bromopyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide; I-7: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-iodopyrimidin-2-yl)amino)cyclohexyl)acetamide; I-8: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((5-nitropyridin-2-yl)amino)cyclohexyl)acetamide; I-9: N-((1r,4r)-4-((5-cyanopyridin-2-yl))amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide; I-10: N-((1r,4r)-4-((7-bromoquinazolin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide; I-11: N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)-N-((1r,4r)-4-((4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide; I-12: N-((1r,4r)-4-((4-(ethylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide; I-13: N-((1r,4r)-4-((4-(ethylamino)-5-fluoropyrimidin-2-yl)amino)cyclohexyl)-N-(4-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)phenyl)acetamide; I-14: N-(4-(N-((1r,4r)-4-((5-chloro-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide; I-15: N-(4-(N-((1r,4r)-4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide; I-16: N-(4-(N-((1r,4r)-4-((4-((3-bromophenyl)amino)-5-chloropyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide; I-17: N-(4-(N-((1r,4r)-4-((5-chloro-4-(4-fluorophenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide; I-18: N-(4-(N-((1r,4r)-4-((5-chloro-4-(4-methoxyphenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide; I-19: N-(4-(N-((1r,4r)-4-((5-chloro-4-((3-fluorophenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide; I-20: N-(4-(N-((1r,4r)-4-((4-((3-acetamidophenyl)amino)-5-chloropyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide; I-21: 2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)-N-(4-(N-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)acetamyl)phenyl)benzamide; I-22: N-(3-(N-((1r,4r)-4-((5-chloropyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide; I-23: N-(3-(N-((1r,4r)-4-((5-cyanopyrimidine-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide; I-24: N-(3-(N-((1r,4r)-4-((5-chloro-4-(4-methoxyphenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide; I-25: N-(3-(N-((1r,4r)-4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)cyclohexyl)acetamyl)phenyl)-2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide.
5. A method for preparing the CDK12 / PARP dual-target inhibitor of claim 1, characterized in that, Includes the following steps: Step 1: Step Two: Step 3: Step Four: Where A and Ar are defined as in claim 1, and X is chlorine; In step four, the solvent is dioxane hydrochloride solution. The reaction is stirred at room temperature until Boc is completely removed. Anhydrous diethyl ether is added to the reaction solution, the mixture is sonicated, the liquid is poured out, and the solution is washed with anhydrous diethyl ether. The solvent is removed under vacuum. Ar-X, DIPEA, and dry NMP were then added, and the mixture was stirred at 100-150°C under nitrogen protection. The reaction was monitored by TLC until it ended. The mixture was then extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, mixed with silica gel, and subjected to column chromatography to obtain the CDK12 / PARP dual-target inhibitor.
6. Use of any one of the CDK12 / PARP dual-target inhibitors according to claims 1-5 in the preparation of a medicament for adjuvant cancer treatment.
7. The use of any one of the CDK12 / PARP dual-target inhibitors according to claims 1-5 in the preparation of a medicament for inhibiting cancer cell proliferation in vitro.
8. The application according to any one of claims 6-7, characterized in that... The cancer mentioned is one or more of the following: breast cancer, ovarian cancer, lung cancer, hematologic malignancies, prostate cancer, pancreatic cancer, and stomach cancer.
9. The application according to any one of claims 6-7, characterized in that, The cancer mentioned is lymphoma.
10. Use of any one of the CDK12 / PARP dual-target inhibitors, its salt, or its stereoisomers in the preparation of CDK12 inhibitors and / or PARP inhibitors according to any one of claims 1-5.
Citation Information
Patent Citations
Aminopyridine compound of phthalidazinone, preparation method of aminopyridine compound and application of aminopyridine compound in preparation of inhibitors and antitumor drugs
CN117683020A
PARP1 / CDK6 double-target inhibitor as well as preparation method and application thereof
CN119552166A
